The correlation between insulin-like growth factor binding protein 1 (IGFBP-1) and homeostasis model assessment of insulin resistance (HOMA-IR) in polycystic ovarian syndrome with insulin resistance

Background: The underlying etiology of polycystic ovarian syndrome (PCOS) is unknown and assumed to have a strong correlation with insulin resistance. Homeostasis Model Assessment of insulin resistance (HOMA-IR) is a good tool to assess insulin resistance. Low levels of serum Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) in PCOS women led to the hypothesis that hyperinsulinemia in PCOS inhibits the production of IGFBP-1, which in turn stimulates excessive androgen production. Objective: The study is aimed to analyze the correlation between the levels of IGFBP-1 and HOMA-IR on insulin resistance in PCOS. Materials and Methods: A cross-sectional study among 105 PCOS women, including 60 women with insulin resistance were recruited. The mean of IGFBP-1 and HOMA-IR were 6.507±4.7821 μg/l and 3.633±1.666 respectively. Results: Low levels of IGFBP-1 were detected in all insulin resistance women. There was a correlation between HOMA-IR and overweight (p=0.045), while IGFBP-1 showed no correlation with overweight (p=0.106). In addition, no correlation between IGFBP-1 with HOMA-IR as a marker of insulin resistance was detected. Conclusion: Despite the decrease in IGFBP-1, it seems that there is no correlation between IGFBP-1 with HOMA-IR as a marker of insulin resistance.

[1]  Francisco Gude,et al.  Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study , 2013, BMC Endocrine Disorders.

[2]  M. Rattanachaiyanont,et al.  The Usefulness of Homeostatic Measurement Assessment-Insulin Resistance (HOMA-IR) for Detection of Glucose Intolerance in Thai Women of Reproductive Age with Polycystic Ovary Syndrome , 2012, International journal of endocrinology.

[3]  M. Traub.  Assessing and treating insulin resistance in women with polycystic ovarian syndrome. , 2011, World journal of diabetes.

[4]  C. J. Kelly,et al.  Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis. , 2011, Human reproduction update.

[5]  A. Esteghamati,et al.  Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007) , 2010, Nutrition & metabolism.

[6]  R. Barbieri.  Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. , 1994, The Journal of reproductive medicine.

[7]  R. Koistinen,et al.  Insulin-like growth factor-I (IGF-I) inhibits production of IGF-binding protein-1 while stimulating estradiol secretion in granulosa cells from normal and polycystic human ovaries. , 1993, The Journal of clinical endocrinology and metabolism.

[8]  B. Carlsson,et al.  Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. , 1993, Fertility and sterility.

[9]  C. Stuart,et al.  Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. , 1990, American journal of obstetrics and gynecology.

[10]  R. Barbieri,et al.  Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. , 1983, American journal of obstetrics and gynecology.